Intranasal delivery of drug-loaded polymeric nanomicelles for brain targeting: a comprehensive review

1. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, Culpepper WJ, Dorsey ER, Elbaz A, Ellenbogen RG, Fisher JL, Fitzmaurice C, Giussani G, Glennie L, James SL, Johnson CO, Kassebaum NJ, Logroscino G, Marin B, … Vos T (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurology, 18(5), 459–480. https://doi.org/10.1016/s1474-4422(18)30499-x10.1016/s1474-4422(18)30499-x ↗

2. Agrawal M, Ajazuddin Tripathi DK, Saraf S, Saraf S, Antimisiaris SG, Mourtas S, Hammarlund-Udenaes M, Alexander A (2017) Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer’s disease. Journal of Controlled Release 260:61–77. https://doi.org/10.1016/j.jconrel.2017.05.01910.1016/j.jconrel.2017.05.019 ↗

3. World Health Organization. (2019). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia

4. Kapoor A, Hafeez A, Kushwaha P (2024) Nanocarrier mediated intranasal drug delivery systems for the management of parkinsonism: a review. Curr Drug Deliv 21(5):709–725. https://doi.org/10.2174/156720182066623052311425910.2174/1567201820666230523114259 ↗

5. Mirpour S, Turkbey EB, Marashdeh W, El Khouli R, Subramaniam RM (2018) Impact of DAT-SPECT on management of patients suspected of parkinsonism. Clin Nucl Med 43(10):710–714. https://doi.org/10.1097/rlu.000000000000224010.1097/rlu.0000000000002240 ↗

6. Singh B, Pandey S, Rumman M, Gupta M, Mahdi AA (2024) Bacopaside-I ameliorates motor dysfunction and neurodegeneration in rat model of Parkinson’s disease. Naunyn-Schmiedeberg’s Arch Pharmacol. https://doi.org/10.1007/s00210-024-03552-3.Advanceonlinepublication.doi:10.1007/s00210-024-03552-310.1007/s00210-024-03552-3.Advanceonlinepublication.doi:10.1007/s00210-024-03552-3 ↗

7. Rizvi SM, Shaikh S, Naaz D, Shakil S, Ahmad A, Haneef M, Abuzenadah AM (2016) Kinetics and molecular docking study of an anti-diabetic drug glimepiride as acetylcholinesterase inhibitor: implication for Alzheimer’s disease-diabetes dual therapy. Neurochem Res 41(6):1475–1482. https://doi.org/10.1007/s11064-016-1859-310.1007/s11064-016-1859-3 ↗

8. DeTure MA, & Dickson DW (2019) The neuropathological diagnosis of Alzheimer’s disease. Molecular neurodegeneration, 14(1). https://doi.org/10.1186/s13024-019-0333-510.1186/s13024-019-0333-5 ↗

9. Abner EL, Neltner JH, Jicha GA, Patel E, Anderson SL, Wilcock DM, Van Eldik LJ, Nelson PT (2018) Diffuse amyloid-β plaques, neurofibrillary tangles, and the impact of APOE in elderly persons’ brains lacking neuritic amyloid plaques. Journal of Alzheimer’s disease: JAD 64(4):1307–1324. https://doi.org/10.3233/jad-18051410.3233/jad-180514 ↗

10. Furquan A, Hafeez A, Rahman MA (2023) Brain targeting of drugs via intranasal route in conjunction with nanoparticle-based systems: an updated review. J Nanopart Res 25:233. https://doi.org/10.1007/s11051-023-05880-610.1007/s11051-023-05880-6 ↗

11. Alqudah A, Aljabali AA, Gammoh O et al (2024) Advancements in neurotherapeutics: nanoparticles overcoming the blood–brain barrier for precise CNS targeting. J Nanopart Res 26:123. https://doi.org/10.1007/s11051-024-05983-810.1007/s11051-024-05983-8 ↗

12. Morris EK, Daignault-Mill S, Stehbens SJ, Genovesi LA, Lagendijk AK (2023) Addressing blood-brain-tumor-barrier heterogeneity in pediatric brain tumors with innovative preclinical models. Front Oncol. https://doi.org/10.3389/fonc.2023.110152210.3389/fonc.2023.1101522 ↗

13. Xue L, Ding J, Liu Y et al (2024) Strategies and methods of nanocrystal technology for targeting drug delivery. J Nanopart Res 26:114. https://doi.org/10.1007/s11051-024-06025-z10.1007/s11051-024-06025-z ↗

14. Belur LR, Romero M, Lee J, Podetz-Pedersen KM, Nan Z, Riedl MS, Vulchanova L, Kitto KF, Fairbanks CA, Kozarsky KF, Orchard PJ, Frey WH II, Low WC, & McIvor RS (2021) Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in Murine mucopolysaccharidosis type I. Frontiers in Molecular Neuroscience, 14. https://doi.org/10.3389/fnmol.2021.61836010.3389/fnmol.2021.618360 ↗

15. Fahoum F, Eyal S (2023) Intracerebroventricular administration for delivery of antiseizure therapeutics: challenges and opportunities. Epilepsia 64(7):1750–1765. https://doi.org/10.1111/epi.1762510.1111/epi.17625 ↗

16. Slavc I, Cohen-Pfeffer JL, Gururangan S, Krauser J, Lim DA, Maldaun M, Schwering C, Shaywitz AJ, Westphal M (2018) Best practices for the use of intracerebroventricular drug delivery devices. Mol Genet Metab 124(3):184–188. https://doi.org/10.1016/j.ymgme.2018.05.00310.1016/j.ymgme.2018.05.003 ↗

17. Zarif Attalla, K., Hassan, D. H., Teaima, M. H., Yousry, C., El-Nabarawi, M. A., Said, M. A., & Elhabal, S. F. (2025). Enhanced intranasal delivery of atorvastatin via superparamagnetic iron-oxide-loaded nanocarriers: cytotoxicity and inflammation evaluation and in vivo, in silico, and network pharmacology study for targeting glioblastoma management. Pharmaceuticals (Basel, Switzerland), 18(3). https://doi.org/10.3390/ph1803042110.3390/ph18030421 ↗

18. Al-Shoubki AA, Teaima MH, Abdelmonem R, El-Nabarawi MA, Elhabal SF (2024) Potential application of sucrose acetate isobutyrate, and glyceryl monooleate for nanonization and bioavailability enhancement of rivaroxaban tablets. Pharmaceutical Science Advances 2(100015):100015. https://doi.org/10.1016/j.pscia.2023.10001510.1016/j.pscia.2023.100015 ↗

19. El-Nawawy TM, Adel YA, Teaima M, Nassar NN, Nemr AA, Al-Samadi I, El-Nabarawi MA, Elhabal SF (2024) Intranasal bilosomes in thermosensitive hydrogel: advancing desvenlafaxine succinate delivery for depression management. Pharm Dev Technol 29(7):663–674. https://doi.org/10.1080/10837450.2024.237606710.1080/10837450.2024.2376067 ↗

20. Al-Shoubki AA, Teaima MH, Abdelmonem R, El-Nabarawi MA, Elhabal SF (2023) Sucrose acetate isobutyrate (SAIB) and glyceryl monooleate (GMO) hybrid nanoparticles for bioavailability enhancement of rivaroxaban: an optimization study. Pharm Dev Technol 28(10):928–938. https://doi.org/10.1080/10837450.2023.227494410.1080/10837450.2023.2274944 ↗

21. Jones N (2001) The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev 519(1–3):5–19. https://doi.org/10.1016/s0169-409x(01)00172-710.1016/s0169-409x(01)00172-7 ↗

22. Groiss SJ, Wojtecki L, Südmeyer M, Schnitzler A (2009) Deep brain stimulation in Parkinson’s disease. Ther Adv Neurol Disord 2:20–28. https://doi.org/10.1177/175628560933938210.1177/1756285609339382 ↗

23. Nishikawa R, Iwata H, Sakata Y, Muramoto K, Matsuoka T (2021) Safety of Gliadel Implant for malignant glioma: report of postmarketing surveillance in Japan. Neurologia Medica Chirurgica 61:536–548. https://doi.org/10.2176/nmc.oa.2021-002410.2176/nmc.oa.2021-0024 ↗

24. Ghosh M, Roy D, Thakur S, Singh A (2024) Exploring the potential of nasal drug delivery for brain-targeted therapy: a detailed analysis. Biopharm Drug Dispos 45(4–6):161–189. https://doi.org/10.1002/bdd.240010.1002/bdd.2400 ↗

25. Wu D, Chen Q, Chen X, Han F, Chen Z, & Wang Y (2023) The blood–brain barrier: structure, regulation, and drug delivery. Signal transduction and targeted therapy, 8(1). https://doi.org/10.1038/s41392-023-01481-w10.1038/s41392-023-01481-w ↗

26. Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH (2018) Mechanism of intranasal drug delivery directly to the brain. Life Sci 195:44–52. https://doi.org/10.1016/j.lfs.2017.12.02510.1016/j.lfs.2017.12.025 ↗

27. Pires A, Fortuna A, Alves G, Falcão A (2009) Intranasal drug delivery: how, why and what for? Journal of Pharmaceutical Sciences 12:288–311. https://doi.org/10.18433/j3nc7910.18433/j3nc79 ↗

28. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514–516. https://doi.org/10.1038/nn0602-84910.1038/nn0602-849 ↗

29. Kuzmov A, Minko T (2015) Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release 219:500–518. https://doi.org/10.1016/j.jconrel.2015.07.02410.1016/j.jconrel.2015.07.024 ↗

30. Nguyen TT, Nguyen DT, Vo TK, Tran NMA, Nguyen MK, Van Vo T, Van Vo G (2021) Nanotechnology-based drug delivery for central nervous system disorders. Biomed Pharmacother 143:112117. https://doi.org/10.1016/j.biopha.2021.11211710.1016/j.biopha.2021.112117 ↗

31. Lu H, Zhang S, Wang J, & Chen Q (2021). A review on polymer and lipid-based nanocarriers and its application to nano-pharmaceutical and food-based systems. Frontiers in Nutrition, 8. https://doi.org/10.3389/fnut.2021.78383110.3389/fnut.2021.783831 ↗

32. Rao JP, Geckeler KE (2011) Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci 36:887–913. https://doi.org/10.1016/j.progpolymsci.2011.01.00110.1016/j.progpolymsci.2011.01.001 ↗

33. Feng Y, He H, Li F, Lu Y, Qi J, Wu W (2018) An update on the role of nanovehicles in nose-to-brain drug delivery. Drug Discovery Today 23(6):1079–1088. https://doi.org/10.1016/j.drudis.2018.01.00510.1016/j.drudis.2018.01.005 ↗

34. Engelhardt B, Sorokin L (2009) The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Seminars in immunopathology 31:497–511. https://doi.org/10.1007/s00281-009-0177-010.1007/s00281-009-0177-0 ↗

35. Selvaraj K, Gowthamarajan K, Karri VVSR (2018) Nose to brain transport pathways: an overview of the potential of nanostructured lipid carriers in nose-to-brain targeting. Artificial cells, nanomedicine, and biotechnology 46(8):2088–2095. https://doi.org/10.1080/21691401.2017.142007310.1080/21691401.2017.1420073 ↗

36. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64(7):614–628. https://doi.org/10.1016/j.addr.2011.11.00210.1016/j.addr.2011.11.002 ↗

37. Bourganis V, Kammona O, Alexopoulos A, Kiparissides C (2018) Recent advances in carrier-mediated nose-to-brain delivery of pharmaceutics. Eur J Pharm Biopharm 128:337–362. https://doi.org/10.1016/j.ejpb.2018.05.00910.1016/j.ejpb.2018.05.009 ↗

38. Sullivan KJ, & Chang HK (1990) Flow dynamics of the nasal passage. In Respiratory biomechanics (pp. 98–105). Springer New York10.1007/978-1-4612-3452-4_12 ↗

39. Dhuria SV, Hanson LR, & Frey WH 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. Journal of Pharmaceutical Sciences 99(4): 1654–1673. https://doi.org/10.1002/jps.2192410.1002/jps.21924 ↗

40. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5(6):514–516. https://doi.org/10.1038/nn0602-84910.1038/nn0602-849 ↗

41. Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. J Neurosci Methods 171(2):143–157. https://doi.org/10.1016/j.jneumeth.2008.03.00110.1016/j.jneumeth.2008.03.001 ↗

42. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481–496. https://doi.org/10.1016/j.neuroscience.2004.05.02910.1016/j.neuroscience.2004.05.029 ↗

43. Gänger S, Schindowski K (2018) Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics, and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 10(3):116. https://doi.org/10.3390/pharmaceutics1003011610.3390/pharmaceutics10030116 ↗

44. Tortora GJ (1998) Principles of human anatomy, 8th edn. Benjamin/Cummings Science Publishing, Menlo Park

45. Chung S, Peters JM, Detyniecki K, Tatum W, Rabinowicz AL, Carrazana E (2022) The nose has it: opportunities and challenges for intranasal drug administration for neurologic conditions, including seizure clusters. Epilepsy Behavior Reports 21:100581. https://doi.org/10.1016/j.ebr.2022.10058110.1016/j.ebr.2022.100581 ↗

46. Kumar A, Sharma R (2022) Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Investig. https://doi.org/10.1007/s40005-022-00589-510.1007/s40005-022-00589-5 ↗

47. Dhuria SV, Hanson LR, Frey WH II (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(6):2386–2398. https://doi.org/10.1002/jps.2192410.1002/jps.21924 ↗

48. Landis MS, Boyden T, Pegg S (2012) Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective. Ther Deliv 3:195–208. https://doi.org/10.4155/tde.11.14910.4155/tde.11.149 ↗

49. Illum L (2000) Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Biopharm 11:1–18. https://doi.org/10.1016/s0928-0987(00)00087-710.1016/s0928-0987(00)00087-7 ↗

50. Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ (2022) On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today 29(101631):101631. https://doi.org/10.1016/j.apmt.2022.10163110.1016/j.apmt.2022.101631 ↗

51. Charlton ST, Davis SS, Illum L (2008) Nasal administration of an angiotensin antagonist in the rat model: effect of bioadhesive formulations on the distribution of drugs to the systemic and central nervous systems. Drug Delivery 15(6):323–331. https://doi.org/10.1080/107175408020352510.1080/1071754080203525 ↗

52. Striepens N, Kendrick KM, Maier W, Hurlemann R (2013) Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front Neuroendocrinol 32(4):426–450. https://doi.org/10.1016/j.yfrne.2011.07.00110.1016/j.yfrne.2011.07.001 ↗

53. Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H (2019) Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm 565:258–268. https://doi.org/10.1016/j.ijpharm.2019.05.03210.1016/j.ijpharm.2019.05.032 ↗

54. Selvaraj K, Gowthamarajan K, Karri VVSR (2018) Nose to brain transport pathways: an overview of the potential of nanostructured lipid carriers in nose-to-brain targeting. Artificial cells, nanomedicine, and biotechnology 46:2088–2095. https://doi.org/10.1080/21691401.2017.142007310.1080/21691401.2017.1420073 ↗

55. Jeong SH, Jang JH, Lee YB (2021) Oral delivery of topotecan in polymeric nanoparticles: lymphatic distribution and pharmacokinetics. J Control Release 335:86–102. https://doi.org/10.1016/j.jconrel.2021.05.01710.1016/j.jconrel.2021.05.017 ↗

56. Wu H, Hu K, Jiang X (2017) From nose to brain: understanding transport capacity and transport rate of drugs. Acta Pharmaceutica Sinica B 7(3):281–291. https://doi.org/10.1016/j.apsb.2017.03.00410.1016/j.apsb.2017.03.004 ↗

57. Bienenstock J, McDermott MR (2005) Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 206(1):22–31. https://doi.org/10.1111/j.0105-2896.2005.00299.x10.1111/j.0105-2896.2005.00299.x ↗

58. Kumar S, Anselmo AC, Banerjee A, Zakrewsky M, Mitragotri S (2018) Shape and size-dependent immune response to antigen-carrying nanoparticles. J Control Release 286:247–265. https://doi.org/10.1016/j.jconrel.2018.07.04410.1016/j.jconrel.2018.07.044 ↗

59. Oliveira P, Sousa JF (2021) Polymers for the design of drug delivery systems. Polymers 13(9):1365. https://doi.org/10.3390/polym1309136510.3390/polym13091365 ↗

60. Khatri DK, Preeti K, Tonape S, Bhattacharjee S, Patel M, Shah S et al (2023) Nanotechnological advances for nose to brain delivery of therapeutics to improve the Parkinson therapy. Curr Neuropharmacol 21(4):493–516. https://doi.org/10.2174/1570159X2066622050702270110.2174/1570159X20666220507022701 ↗

61. Shim S, Yoo HS (2020) The application of mucoadhesive chitosan nanoparticles in nasal drug delivery. Mar Drugs 18(12):605. https://doi.org/10.3390/md1812060510.3390/md18120605 ↗

62. Nakowitsch S, Koller C, Seifert JM et al (2020) Saponin micelles lead to high mucosal permeation and in vivo efficacy of solubilized budesonide. Pharmaceutics 12(9):847. https://doi.org/10.3390/pharmaceutics1209084710.3390/pharmaceutics12090847 ↗

63. Wang D, Wu X, Gan Z et al (1996) Study on the correlation between nasal ciliary transport function and Qi deficiency in chronic rhinitis. Liaoning Journal of Traditional Chinese Medicine 23(9):392–393

64. Chen S, Zhang J, Wu L, Wu H, Dai M (2018) Paeonol nanoemulsion for enhanced oral bioavailability: optimization and mechanism. Nanomedicine 13:269–282. https://doi.org/10.2217/nnm-2017-027710.2217/nnm-2017-0277 ↗

65. Bors LA, Bajza Á, Mándoki M, Tasi BJ, Cserey G, Imre T et al (2020) Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats. Brain Res Bull 160:65–73. https://doi.org/10.1016/j.brainresbull.2019.12.00510.1016/j.brainresbull.2019.12.005 ↗

66. Kumar NN, Gautam M, Lochhead JJ, Wolak DJ, Ithapu V, Singh V et al (2016) Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: implications for nasal physiology and drug delivery. Sci Rep 6:31732. https://doi.org/10.1038/srep3173210.1038/srep31732 ↗

67. Djupesland PG, Skretting A (2009) Nasal deposition in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv 25:280–289. https://doi.org/10.1089/jamp.2011.092410.1089/jamp.2011.0924 ↗

68. Appu AP, Arun P, Krishnan JK, Moffett JR, Namboodiri AM (2016) Rapid intranasal delivery of chloramphenicol acetyltransferase in the active form to different brain regions as a model for enzyme therapy in the CNS. J Neurosci Methods 259:129–134. https://doi.org/10.1016/j.jneumeth.2015.11.02710.1016/j.jneumeth.2015.11.027 ↗

69. Sakane T, Akizuki M, Yamashita S et al (1991) The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 39(12):2456–2485. https://doi.org/10.1248/cpb.39.245610.1248/cpb.39.2456 ↗

70. Jiang XG, Lu X, Cui JB et al (1997) Studies on octanol-water partition coefficient and nasal drug absorption. Acta Pharmaceutica Sinica 32(5):458–460

71. Chen S, Xie Q, Yang M, Shi Y, Shi J, Zeng X (2022) Scutellaria baicalensis extract-phospholipid complex: preparation and initial pharmacodynamics research in rats. Curr Pharm Biotechnol 23:847–860. https://doi.org/10.2174/138920102266621072914225710.2174/1389201022666210729142257 ↗

72. Hirai S, Yashiki T, Matsuzawa T et al (1981) Absorption of drugs from the nasal mucosa of rats. Int J Pharm 7:317–325. https://doi.org/10.1016/0378-5173(81)90058-210.1016/0378-5173(81)90058-2 ↗

73. Schipper NG, Verhoef JC, Merkus FW (1991) The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 8(7):807–814. https://doi.org/10.1023/a:101583090763210.1023/a:1015830907632 ↗

74. Morawska-Kochman M, Jermakow K, Nelke K et al (2019) The pH value as a factor modifying bacterial colonization of sinonasal mucosa in healthy persons. Annals of otology, rhinology & laryngology 128(9):819–828. https://doi.org/10.1177/000348941984314310.1177/0003489419843143 ↗

75. Khan MI, Bhatnagar A, Lee D (2018) Viscosity of nasal formulations and its effect on nasal drug delivery: a review. J Control Release 271:103–116

76. England RJ, Homer JJ, Knight LC, Ell SR (1999) Nasal pH measurement: a reliable and repeatable parameter. Clin Otolaryngol 24:67–68. https://doi.org/10.1046/j.1365-2273.1999.00223.x10.1046/j.1365-2273.1999.00223.x ↗

77. National Pharmacopoeia Commission. (2020). Pharmacopoeia of the People’s Republic of China (part IV). China Medical Science and Technology Press

78. Lemoine JL, Farley R, Huang L (2005) Mechanism of efficient transfection of the nasal airway epithelium by hypotonic shock. Gene Ther 12:1275–1282. https://doi.org/10.1038/sj.gt.330254810.1038/sj.gt.3302548 ↗

79. Khan AR, Liu M, Khan MW, Zhai G (2017) Progress in brain targeting drug delivery system by nasal route. J Control Release 268:364–389. https://doi.org/10.1016/j.jconrel.2017.09.00110.1016/j.jconrel.2017.09.001 ↗

80. Pardeshi CV, Rajput PV, Belgamwar VS, Tekade AR, Surana SJ (2013) Novel surface modified solid lipid nanoparticles as intranasal carriers for ropinirole hydrochloride: application of factorial design approach. Drug Delivery 20:47–56. https://doi.org/10.3109/10717544.2012.75242110.3109/10717544.2012.752421 ↗

81. Dahlin M, Jansson B, Björk E (2001) Levels of dopamine in blood and brain following nasal administration to rats. Eur J Pharm Sci 14:75–80. https://doi.org/10.1016/s0928-0987(01)00151-810.1016/s0928-0987(01)00151-8 ↗

82. Thorne RG, Emory CR, Ala TA, Frey WH (1995) Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 692:278–282. https://doi.org/10.1016/0006-8993(95)00637-610.1016/0006-8993(95)00637-6 ↗

83. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Buadze M, Geisler J, Klopfer T, Burkhardt U, Proksch B, Verleysdonk S, Ayturan M et al (2009) Intranasal delivery of cells to the brain. Eur J Cell Biol 88(5):315–324. https://doi.org/10.1016/j.ejcb.2009.02.00110.1016/j.ejcb.2009.02.001 ↗

84. Aqeel R, Srivastava N, Kushwaha P (2022) Micelles in cancer therapy: an update on preclinical and clinical status. Recent Pat Nanotechnol 16(4):283–294. https://doi.org/10.2174/187221051566621072012571710.2174/1872210515666210720125717 ↗

85. Talelli M, Hennik WE (2011) Thermosensitive polymeric micelles for targeted drug delivery. Nanomedicine 6(5):1245–1255. https://doi.org/10.2217/nnm.11.9110.2217/nnm.11.91 ↗

86. Abuwatfa WH, Awas NS, Pitt WG, Husseini GA (2022) Thermosensitive polymers and thermo-responsive liposomal drug delivery systems. Polymers 14(5):925. https://doi.org/10.3390/polym1405092510.3390/polym14050925 ↗

87. Zhang W, Zhang Q, Yang Y, Chen Y, Wei J, Lu F, Li D (2025) Multi-functional Chitosan polymeric micelles for improving the oral bioavailability of Paclitaxel based on synergistic effect. Drug Deliv Transl Res 15(1):312–324. https://doi.org/10.1007/s13346-024-01597-810.1007/s13346-024-01597-8 ↗

88. Shalmani AA, Wang A, Ahmed Z, Sheybanifard M, Mihyar R, Buhl EM, Pohl M, Hennink WE, Kiessling F, Metselaar JM, Shi Y, Lammers T, Peña Q (2024) Tunable polymeric micelles for taxane and corticosteroid co-delivery. Drug Deliv Transl Res 14(10):2642–2654. https://doi.org/10.1007/s13346-023-01465-x10.1007/s13346-023-01465-x ↗

89. Francis MF, Cristea M, Winnik FM (2004) Polymeric micelles for oral drug delivery: why and how. Pure Appl Chem 76(7–8):1321–1335. https://doi.org/10.1351/pac20047607132110.1351/pac200476071321 ↗

90. Gaucher G, Satturwar P, Jones M-C, Furtos A, Leroux J-C (2010) Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm 76(2):147–158. https://doi.org/10.1016/j.ejpb.2010.06.00710.1016/j.ejpb.2010.06.007 ↗

91. Srivalli KMR, Lakshmi PK (2012) Overview of P-glycoprotein inhibitors: A rational outlook. Braz J Pharm Sci 48(3):353–367. https://doi.org/10.1590/s1984-8250201200030000210.1590/s1984-82502012000300002 ↗

92. Limongi T, Susa F, Marini M, Allione M, Torre B, Pisano R, di Fabrizio E (2021) Lipid-based nanovesicular drug delivery systems. Nanomaterials (Basel, Switzerland) 11(12):3391. https://doi.org/10.3390/nano1112339110.3390/nano11123391 ↗

93. Gao W, Hu C-MJ, Fang RH, & Zhang L (2013) Liposome-like nanostructures for drug delivery. Journal of Materials Chemistry. B, Materials for Biology and Medicine, 1(48). https://doi.org/10.1039/C3TB21238F10.1039/C3TB21238F ↗

94. Bartelds R, Nematollahi MH, Pols T, Stuart MCA, Pardakhty A, Asadikaram G, Poolman B (2018) Niosomes, an alternative for liposomal delivery. PLoS ONE 13(4):e0194179. https://doi.org/10.1371/journal.pone.019417910.1371/journal.pone.0194179 ↗

95. Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P (2023) Solid lipid nanoparticles vs. Nanostructured lipid carriers: a comparative review. Pharmaceutics 15(6):1593. https://doi.org/10.3390/pharmaceutics1506159310.3390/pharmaceutics15061593 ↗

96. IUPAC. (1997). Compendium of chemical terminology (2nd ed.). Oxford: Blackwell Scientific Publications. https://doi.org/10.1351/goldbook.M0388910.1351/goldbook.M03889 ↗

97. Kocak G, Tuncer CA, Bütün VJ (2016) pH-responsive polymers. Polym Chem 8(1):144–176. https://doi.org/10.1039/c6py01872f10.1039/c6py01872f ↗

98. Slomkowski S, Alemán JV et al (2011) Terminology of polymers and polymerization processes in dispersed systems (IUPAC recommendations 2011). Pure Appl Chem 83(12):2229–2259. https://doi.org/10.1351/PAC-REC-10-06-0310.1351/PAC-REC-10-06-03 ↗

99. Kedar, U., Phutane, P., Shidhaye, S., & Kadam, V. (2010). Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine: nanotechnology, biology, and medicine, 6(6), 714–729. https://doi.org/10.1016/j.nano.2010.05.00510.1016/j.nano.2010.05.005 ↗

100. Li X, Gao Y, Boott CE, Winnik MA, Manners I (2015) Non-covalent synthesis of supermicelles with complex architectures using spatially confined hydrogen-bonding interactions. Nat Commun 6:8127. https://doi.org/10.1038/ncomms912710.1038/ncomms9127 ↗